Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Net Income towards Common Stockholders (2020 - 2024)

Immuneering (IMRX) has 5 years of Net Income towards Common Stockholders data on record, last reported at -$18.1 million in Q4 2024.

  • For Q4 2024, Net Income towards Common Stockholders fell 16.69% year-over-year to -$18.1 million; the TTM value through Dec 2024 reached -$61.5 million, down 12.17%, while the annual FY2024 figure was -$61.5 million, 12.17% down from the prior year.
  • Net Income towards Common Stockholders reached -$18.1 million in Q4 2024 per IMRX's latest filing, down from -$14.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$3.6 million in Q2 2020 and bottomed at -$18.1 million in Q4 2024.
  • Average Net Income towards Common Stockholders over 5 years is -$11.6 million, with a median of -$12.9 million recorded in 2022.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 121.47% in 2021, then decreased 0.81% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.4 million in 2020, then plummeted by 149.44% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023, then dropped by 16.69% to -$18.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$18.1 million in Q4 2024, -$14.7 million in Q3 2024, and -$14.1 million in Q2 2024.